Form 4: Amgen SVP Rachna Khosla Reports Stock and Option Awards

Rachna Khosla, SVP of Business Development at Amgen, reports the acquisition of restricted stock units and non-qualified stock options.

Summary

• On May 7, 2024, Rachna Khosla, SVP of Business Development at Amgen, reported transactions related to Amgen stock.
• Khosla acquired 532 shares of common stock in the form of Restricted Stock Units (RSUs).
• These RSUs vest in three annual installments starting May 7, 2026.
• Khosla also acquired 3,461 non-qualified stock options with an exercise price of $300.30.
• These options are exercisable in three annual installments starting May 7, 2026.
• Following the reported transactions, Khosla beneficially owns 8,559 shares of Amgen common stock.
• This includes previously granted RSUs and dividend equivalents (DEs) that vest over time.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects standard executive compensation practices, aligning executive interests with company performance. There are no indications of negative events or concerns.

Positives

• The grant of RSUs and stock options to a key executive like Rachna Khosla aligns her interests with the long-term performance of Amgen.
• The vesting schedules of the RSUs and stock options incentivize continued service and contribution to the company's success.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedules of the granted RSUs and stock options.

Industry Context

Stock and option awards are a common practice in the pharmaceutical industry to incentivize and retain key executives. These awards align executive compensation with company performance and shareholder value.

Comparison to Industry Standards

• Amgen's equity compensation practices are generally in line with industry standards for large-cap biotechnology companies.
• Companies like Gilead Sciences, Biogen, and AbbVie also utilize stock options and restricted stock units as part of their executive compensation packages.
• The vesting schedules and exercise prices are typically structured to incentivize long-term value creation.

Stakeholder Impact

• The grant of equity to executives can positively impact shareholders by aligning management's interests with long-term company performance.
• Employees may view executive compensation packages as a sign of the company's commitment to its leadership.

Key Dates